Treatment FAQ

what is wac of hcv treatment

by Prof. Bettie Pfannerstill Published 3 years ago Updated 2 years ago
image

According to the New York Times, the pill has a projected WAC of $28,000 for a 4-week treatment, or $1,000 per daily pill. That translates to $84,000 for the 12-week treatment cycle recommended for most patients, and $168,000 for the 24 weeks needed for a hard-to-treat strain of the virus.

Full Answer

Is HCV treatment cost-effective?

Oct 26, 2021 · Without treatment, chronic hepatitis C can cause scarring of the liver , which can cause the liver to stop working properly. ... However, the average negotiated discount of 22% in 2014 increased to 46% less than the WAC in 2015, implying that many payers are paying well below the WAC for HCV medications .

How is hepatitis C virus (HCV) infection treated?

Mar 14, 2022 · Current treatment for chronic hepatitis C (CHC) is highly efficacious, well-tolerated, and of short duration for the majority of patients. Despite the dramatic advances in therapy, there remain several barriers to disease eradication. These include deficiencies ...

Who pays for HCV treatment?

Jun 11, 2021 · Download PDF 0.5MB. Share. Sovaldi, a direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV), had an average wholesale acquisition cost (WAC) of $1,000 per day in 2013, or $84,000 for a 12-week course of treatment. Sovaldi’s launch kicked off the second generation of DAAs for HCV, which expanded more widely tolerable treatment options to …

How has the Pharmacoeconomics of HCV treatment changed?

when comparing the cost of a drug to the lifetime cost of chronic disease •Gilead is working with public and private payers around the world to help ensure patient access to Sovaldi as quickly as possible *Wholesale Acquisition Cost (WAC) per patient and corresponding treatment duration for HCV Genotype 1 regimens.

image

What is the cost of HCV treatment?

A 2018 study found that a single pill of one hepatitis C drug cost $1,000. The total was $84,000 for its 12-week course of treatment. Another drug cost $23,600 per month. That's for treatment that could take 6 months to a year.Jun 26, 2020

What is the best treatment of HCV?

Hepatitis C is treated using direct-acting antiviral (DAA) tablets. DAA tablets are the safest and most effective medicines for treating hepatitis C. They're highly effective at clearing the infection in more than 90% of people.

What are the four drugs used to treat HCV?

Here are the medications available to treat hepatitis C, plus some helpful information about what to expect with their treatment.Ribavirin. ... Direct-acting antivirals (DAAs) ... Combination drugs. ... Ledipasvir-sofosbuvir (Harvoni) ... Elbasvir-grazoprevir (Zepatier) ... Sofosbuvir-velpatasvir (Epclusa)More items...

WHO guidelines HCV treatment?

WHO recommends therapy with pan-genotypic direct-acting antivirals (DAAs) for persons over the age of 12 years. DAAs can cure most persons with HCV infection, and treatment duration is short (usually 12 to 24 weeks), depending on the absence or presence of cirrhosis.Jul 27, 2021

Can HCV be cured?

Today, chronic HCV is usually curable with oral medications taken every day for two to six months. Still, about half of people with HCV don't know they're infected, mainly because they have no symptoms, which can take decades to appear.Aug 31, 2021

How long is treatment for hep C?

How long does it take to cure hepatitis C? Depending on the drug combination, the specific genotype of hepatitis C that is to be treated, any prior treatment, and whether the person has cirrhosis, the duration of medical therapy may be as few as 8 weeks, or up to 24 weeks. Most regimens are for 12 consecutive weeks.

Which type of hepatitis is more severe?

Hepatitis Delta is considered to be the most severe form of hepatitis because of its potential to quickly lead to more serious liver disease than hepatitis B alone. Of the 292 million people living with chronic hepatitis B, approximately 15-20 million are also living with hepatitis D.Jan 9, 2019

Which hepatitis is not curable?

How to prevent hepatitis B. Hepatitis B is a liver infection caused by a virus (called the hepatitis B virus, or HBV). It can be serious and there's no cure, but the good news is it's easy to prevent.

Is hep C treatment like chemo?

The chemotherapy that you'd get for cancer isn't used to treat hepatitis C. But Bacon says hepatitis C treatment can have side effects "that are akin to what patients experience when they receive cancer chemotherapy." That includes temporary hair loss.Sep 10, 2008

How long does Hep C take to damage liver?

After many years some people will have minimal liver damage with no scarring while others can progress to cirrhosis (extensive scarring of the liver) within less than ten years. On average it takes about twenty years for significant liver scarring to develop.

What is the main cause of Hep C?

Hepatitis C is a liver infection caused by the hepatitis C virus (HCV). Hepatitis C is spread through contact with blood from an infected person. Today, most people become infected with the hepatitis C virus by sharing needles or other equipment used to prepare and inject drugs.

How do you know if your Hep C is getting worse?

Symptoms of end-stage liver disease may include:Easy bleeding or bruising.Persistent or recurring yellowing of your skin and eyes (jaundice)Intense itching.Abdominal pain.Loss of appetite.Nausea.Swelling due to fluid buildup in your abdomen and legs.Problems with concentration and memory.

What is cost effectiveness analysis?

Cost-effectiveness analysis (CEA) compares the relative costs and outcomes of 2 or more interventions. CEA explicitly recognizes budget limitations for healthcare spending and seeks to maximize public health benefits within those budgetary constraints. The core question that CEA addresses is whether to invest limited healthcare dollars in a new treatment/therapy or use that money to invest in another healthcare intervention that would provide better outcomes for the same monetary investment. The focus of CEA is, therefore, not simply cost or saving money but health benefits. It assumes that all available resources will be spent and provides a framework for prioritizing among available treatment options by formally assessing the comparative costs and health benefits accrued from a new treatment relative to current treatment.

What is the time horizon for CEA?

From a societal perspective, CEA uses a lifetime time horizon, meaning it considers lifetime costs and benefits, including those that occur in the distant future. Business budget planning, however, typically assumes a 1-year to 5-year perspective.

What does private insurance do?

Private insurance companies often have separate pharmacy and medical budgets, and use PBMs or directly negotiate drug pricing with pharmaceutical companies. Insurance companies determine formulary placement, which impacts the choice of regimens and out-of-pocket expenses for patients.

Is life expectancy a measure of benefit?

Life expectancy is a valuable measure of benefit but considering only mortality benefits fails to recognize the value of treatments that improve quality of life. The quality-adjusted life-year (QALY) provides a measure that integrates both longevity and quality of life and is the preferred outcome for CEA.

Is an intervention cost effective?

An intervention that is cost-effective is not necessarily affordable. Affordability refers to whether a payer has sufficient resources in its annual budget to pay for a new therapy for all who might need or want it within that year . Several characteristics of CEA limit its ability to speak to the budgetary impact of interventions being implemented in the real world.

Is HCV cost effective?

There is no formula that provides a good means of integrating the concerns of value and affordability. When new HCV therapies are deemed cost-effective, it indicates that these therapies provide good benefit for the resources invested and providing such therapy to more people would be a good long-term investment.

Is routine HCV testing cost effective?

Generally, routine HC V testing is cost-effective because the incidence and prevalence of HCV remain high in people who inject drugs with a notable rising prevalence in young adults who may not readily report their stigmatized risk behaviors.

How high is the cure rate for hepatitis C?

Driven by several novel regimens recently receiving approval in the US and in Europe, high cure rates exceeding 90% are now achievable for most patients suffering from chronic hepatitis C. As a result of this unprecedented success, the industry is reaching a new phase in the fight against this deadly infectious disease. The pressure is now shifting to the healthcare providers to determine if the future of hepatitis C treatment will include a (near) eradication in the developed world, or if hepatitis C will remain a debilitating and life-threatening factor in our society.

How long does it take to cure hepatitis C?

The ability to cure over 95% of many patient populations, simultaneously shortening treatment durations to 12 weeks with a once-daily single pill, while also eliminating peginterferon and ribavirin for most patients, truly revolutionized the hepatitis C treatment paradigm.

When did Epclusa come out?

The launch of Gilead’s Epclusa (sofosbuvir/velpatasvir) in July 2016 in the US was only the first in a row of pan-genotypic treatment alternatives.

Who is Mirco Junker?

Mirco Junker, PhD, is an Analyst covering Infectious Diseases at research and consulting firm GlobalData. He extensively researches and provides in-depth analysis on a wide range of topics in the infectious diseases space, including hepatitis C therapeutics and vaccine research, development, and immunization policy.

How long does Harvoni work?

Harvoni already demonstrated high efficacy after 8 weeks of treatment in patients with GT1 and no cirrhosis, and both Gilead and Janssen are currently developing possible pan-genotypic DAAs that might be able to cure the same patient population after only 6 weeks of treatment.

How many people have been treated with Sovaldi?

However, several factors are driving the market toward more inclusive national treatment approaches. In the past 3 years alone, over 1 million people have been treated with Sovaldi-based regimens. Since most of these people will have been cleared of the virus, the total prevalence in most of the 9MM is now slowly decreasing.

Is HCV a curable disease?

The treatment of chronic HCV has undergone a seismic shift during the past few years and HCV can now be considered a curable disease in most patient populations. This success story also translates into higher barriers for companies, as intense competition limits market access while simultaneously the population pool targeted by these drugs is expected to decline in the next decade.

How Do You Treat Hepatitis C?

Medications known as direct acting antivirals, or DAAs, stop the hep C virus from making copies of itself. Some of the newer DAAs appear to work well on all types of hepatitis C. (Each type of hep C is known as a genotype because of its different genetic makeup.)

Does SVR Mean Cured?

If blood tests can’t detect hep C 12 weeks or more after you finish treatment, in 99% of cases you'll stay free of the virus for the rest of your life.

Does SVR Help My Liver?

SVR stops damage to your liver from hepatitis C. It can slow or stop liver disease if you have it. Your liver starts to do its job better, and important substances called enzymes usually return to normal levels. It might even improve your results of treatment for liver cancer.

image

Drug Cost and Reimbursement

  • Many organizations are involved with hepatitis C drug distribution and each can impact costs as well as decisions about which regimens are reimbursed (US GAO, 2015); (US CBO, 2015). The roles these organizations have in determining the actual price paid for drugs and who has access to treatment include the following: 1. Pharmaceutical companies determine the wholesale acqui
See more on hcvguidelines.org

Cost-Effectiveness

  • Cost-effectiveness analysis (CEA) compares the relative costs and outcomes of 2 or more interventions. CEA explicitly recognizes budget limitations for healthcare spending and seeks to maximize public health benefits within those budgetary constraints. The core question that CEA addresses is whether to invest limited healthcare dollars in a new treatment/therapy or use that …
See more on hcvguidelines.org

Affordability

  • An intervention that is cost-effective is not necessarily affordable. Affordability refers to whether a payer has sufficient resources in its annual budget to pay for a new therapy for all who might need or want it within that year. Several characteristics of CEA limit its ability to speak to the budgetary impact of interventions being implemented in the real world. 1. Perspective on cost CEA seeks t…
See more on hcvguidelines.org

Cost vs Affordability For HCV Treatment

  • Despite a growing body of evidence that HCV treatment is cost-effective and may even be cost saving over the long term in some cases, many US payers—especially those offering Medicaid insurance products—continue to limit access to HCV treatment. Access has improved as cost has decreased but limitations remain. Proposed reductions in healthcare spending for Medicaid wou…
See more on hcvguidelines.org

Cost-Effectiveness of Screening For HCV

  • Several cost-effectiveness studies demonstrate that routine, one-time testing for HCV among all adults in the US would likely identify a substantial number of cases of HCV that are currently being missed, and that doing so would be cost-effective. One study employed simulation modeling to compare several versions of routine guidance, including routine testing for adults over the ages …
See more on hcvguidelines.org

Conclusions

  • Many studies have demonstrated the economic value of HCV screening (Chaillon, 2019); (Eckman, 2019); (Tasillo, 2019); (Assoumou, 2018); (Barocas, 2018); (Schackman, 2018); (Schechter-Perkins, 2018); (Lyons, 2016); (Hsieh, 2016); (Schackman, 2015) and treatment (Goel, 2018); (Chhatwal, 2017); (He, 2017); (Chahal, 2016); (Chhatwal, 2015); (Chidi, 2016); (Martin, 201…
See more on hcvguidelines.org

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 1 2 3 4 5 6 7 8 9